Key Points
- Edwards VP Donald Bobo Jr. sold 11,340 shares on Dec. 10 at an average price of $83.83 for about $950,632, reducing his holding by 18.38% to 50,356 shares (valued ≈ $4.22M); the sale was disclosed in an SEC filing.
- Edwards beat quarterly estimates with $0.67 EPS and $1.55B revenue (up 14.7% YoY), issued FY2025 guidance of 2.560–2.620 EPS, and carries a consensus analyst rating of "Moderate Buy" with a $93.09 target.
Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Donald Bobo, Jr. sold 11,340 shares of the stock in a transaction that occurred on Wednesday, December 10th. The shares were sold at an average price of $83.83, for a total transaction of $950,632.20. Following the completion of the transaction, the vice president owned 50,356 shares in the company, valued at $4,221,343.48. This represents a 18.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Edwards Lifesciences Stock Up 0.8%
Shares of NYSE:EW opened at $83.97 on Thursday. The firm has a 50 day simple moving average of $81.34 and a 200-day simple moving average of $78.92. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.89. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $48.73 billion, a PE ratio of 36.19, a P/E/G ratio of 3.74 and a beta of 0.97.
Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period last year, the business earned $0.67 EPS. Edwards Lifesciences's revenue for the quarter was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.
Institutional Investors Weigh In On Edwards Lifesciences
Several large investors have recently modified their holdings of EW. Vanguard Group Inc. grew its position in Edwards Lifesciences by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company's stock valued at $5,472,147,000 after buying an additional 365,581 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Edwards Lifesciences by 4.9% in the 3rd quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company's stock worth $1,617,959,000 after acquiring an additional 977,933 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Edwards Lifesciences by 8.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company's stock worth $1,478,425,000 after acquiring an additional 1,423,365 shares during the period. Jennison Associates LLC boosted its holdings in shares of Edwards Lifesciences by 19.6% in the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company's stock valued at $1,085,574,000 after acquiring an additional 2,287,783 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Edwards Lifesciences by 0.4% during the second quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company's stock worth $990,074,000 after acquiring an additional 45,555 shares during the period. Hedge funds and other institutional investors own 79.46% of the company's stock.
Analyst Ratings Changes
Several analysts have recently weighed in on the company. Evercore ISI boosted their target price on Edwards Lifesciences from $88.00 to $92.00 and gave the company an "outperform" rating in a report on Friday, October 31st. Wall Street Zen lowered Edwards Lifesciences from a "strong-buy" rating to a "buy" rating in a research report on Monday, September 29th. Mizuho increased their price objective on Edwards Lifesciences from $90.00 to $100.00 and gave the company an "outperform" rating in a report on Friday, October 31st. Raymond James Financial upgraded shares of Edwards Lifesciences from a "market perform" rating to an "outperform" rating and set a $96.00 target price on the stock in a research report on Monday, November 3rd. Finally, Wells Fargo & Company reiterated an "overweight" rating and issued a $96.00 price target (up previously from $95.00) on shares of Edwards Lifesciences in a research report on Friday, December 5th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of "Moderate Buy" and a consensus target price of $93.09.
Get Our Latest Stock Report on EW
Edwards Lifesciences Company Profile
(
Get Free Report)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
